朱君瑶,史忠亮,郭力恒

• 1:广州中医药大学
• 2:广州中医药大学第二附属医院

摘要(Abstract)：

脓毒症是一种发病率、病死率均较高的严重疾病,且目前未存在特效药物可干预。川芎嗪为中药川芎的主要活性成分之一,可通过抗炎、清除氧自由基、保护重要脏器等作用来缓解脓毒症的临床症状,减少并发症的发生。但目前川芎嗪治疗脓毒症的高质量的临床研究较少,具体机制尚不完全明确,需进一步研究川芎嗪发挥作用的具体机制和投入更多的临床研究。

关键词(KeyWords)： 川芎嗪;脓毒症;机制;综述

Abstract:

Keywords:

基金项目(Foundation): 国家自然科学基金项目（81673702）;; 广东省自然科学基金项目（2017A030313725,2016A030313636）;; 广东省中医院史载祥名医传承工作室

作者(Author): 朱君瑶,史忠亮,郭力恒

参考文献(References)：

• [1] Rhodes A,Evans L E,Alhazzani W,et al. Surviving sepsis campaign:international guidelines for management of sepsis and septic shock:2016[J]. Intensive care medicine,2017,43(3):304-377.
• [2] Angus DC,Linde-Zwirble WT,Lidicker J,et al. Epidemiology of severe sepsis in the United States:analysis of incidence,outcome,and associated costs of care[J]. Critical care medicine,2001,29(7):1303-1310.
• [3] Aziz M,Jacob A,Yang WL,et al. Current trends in inflammatory and immunomodulatory mediators in sepsis[J]. Journal of leukocyte biology,2013,93(3):329-342.
• [4] Vincent JL,Marshall JC,?amendys-Silva SA,et al. Assessment of the worldwide burden of critical illness:the intensive care over nations(ICON)audit[J]. The lancet Respiratory medicine,2014,2(5):380-386.
• [5] Rhee C,Dantes R,Epstein L,et al. Incidence and trends of sepsis in US hospitals using clinical vs claims data,2009-2014[J]. Jama,2017,318(13):1241-1249.
• [6] Zhou J,Tian H,Du X,et al. Population-based epidemiology of sepsis in a subdistrict of Beijing[J]. Critical care medicine,2017,45(7):1168-1176.
• [7] Riewald M,Ruf W. PAR1-signaling by activated protein C in cytokine perturbed endothelial cells is distinct from thrombin signaling[J]. Journal of Biological Chemistry,2005.
• [8] Ward PA,Bosmann M. A historical perspective on sepsis[J].The American journal of pathology,2012,181(1):2-7.
• [9]曹钰，柴艳芬，邓颖，等.中国脓毒症/脓毒性休克急诊治疗指南（2018)[J].临床急诊杂志，2018,19(9):567-588.
• [10] Ran X,Ma L,Peng C,et al. Ligusticum chuanxiong Hort:a review of chemistry and pharmacology[J]. Pharmaceutical Biology,2011,49(11):1180-1189.
• [11] Ichinose F,Buys ES,Neilan TG,et al. Cardiomyocyte-specific overexpression of nitric oxide synthase 3 prevents myocardial dysfunction in murine models of septic shock[J]. Circulation research,2007,100(1):130-139.
• [12] Rudiger A,Singer M. Mechanisms of sepsis-induced cardiac dysfunction[J]. Critical care medicine,2007,35(6):1599-1608.
• [13]姜宇懋，王丹巧.川芎嗪药理作用研究进展[J].中国现代中药，2016,18(10):1364-1370.
• [14]陈创杰.川芎嗪治疗严重脓毒症心肌损伤的临床研究[J].基层医学论坛，2011,15(34):1097-1099.
• [15]胡丹丹，楼黎明.氧自由基、HMGB1在脓毒症大鼠心肌组织中的动态表达及丹红注射液的干预影响[J].中华中医药学刊，2016,34(1):163-166.
• [16]李向东.川芎嗪对心肺复苏后脑缺血再灌注损伤的临床研究[J].中国临床研究，2011,3(16):79.
• [17]王齐荣.川芎嗪对心肺复苏后脑缺血再灌注损伤的临床研究[J].中国实用医学，2012,7(17):157.
• [18]刘国敏.观察川芎嗪对心肺复苏后脑损伤的保护作用及其机制[J].临床与实践，2014,12(8):30.
• [19] Devi Ramnath R,Weing S,He M,et al. Inflammatory mediators in sepsis:cytokines,chemokines,adhesion molecules and gases[J]. Journal of Organ Dysfunction,2006,2(2):80-92.
• [20] Lakhani SA,Bogue CW. Toll-like receptor signaling in sepsis[J]. Current opinion in pediatrics,2003,15(3):278-282.
• [21] Hoesel L M,Neff TA,Neff SB,et al. Harmful and protective roles of neutrophils in sepsis[J]. Shock,2005,24(1):40-47.
• [22]李荣，张珍祥.川芎嗪对内毒素血症小鼠血清一氧化氮、肿瘤坏死因子-α仅和白三烯D4含量的影响[J].中国中西医结合杂志，2002(S1):214-216.
• [23]曾韬.川芎嗪对脓毒症小鼠肺内炎症损伤的影响[J].荆楚理工学院学报，2010,25(2):16-19.
• [24]路东明，汪栋，韩开宝.川芎嗪对体外循环中炎性因子IL-8、TNF-α的影响[J].山东医药，2007,51(19):108-109.
• [25] Gu WJ,Wan YD,Tie HT,et al. Risk of acute lung injury/acute respiratory distress syndrome in critically ill adult patients with pre-existing diabetes:a meta-analysis[J]. PloS one,2014,9(2):e90426.
• [26]曹钰，柴艳芬，邓颖，等.中国脓毒症/脓毒性休克急诊治疗指南（2018)[J].临床急诊杂志，2018,19(9):567-588.
• [27]梁剑平，郭伟洪，黄宇筠.无创正压通气治疗急性肺损伤的临床效果[J].广东医学，2014,35(14):2240-2242.
• [28]王慧琦，陈远卓，李丛烨，等.川芎嗪对脓毒症急性肺损伤的保护作用[J].同济大学学报：医学版，2014,35(5):20-25.
• [29]刘丹，周发春.川芎嗪对脓毒症诱导的急性肺损伤小鼠血管内皮生长因子水平变化的影响[J].中国生物制品学杂志，2011,24(2):199-202.
• [30]黄旺业，黄庆，曾德福，等.川芎嗪在脓毒症致急性肺损伤患者中的应用效果[J].广西医学，2018,40(1):94-96.
• [31] Merx MW,Weber C. Sepsis and the heart[J]. Circulation,2007,116(7):793-802.
• [32] Landesberg G,Gilon D,Meroz Y,et al. Diastolic dysfunction and mortality in severe sepsis and septic shock[J]. European Heart Journal,2011,33(7):895-903.
• [33] Zanotti-Cavazzoni SL,Hollenberg SM. Cardiac dysfunction in severe sepsis and septic shock[J]. Current Opinion in Critical Care,2009,15(5):392-397.
• [34]杨澄，张敏州，郭力恒，等.川芎嗪对脓毒症大鼠心功能保护作用的研究[J].时珍国医国药，2011,22(9):2302-2303.
• [35]杨澄.川芎嗪治疗严重脓毒症心肌损伤作用及其抗氧化机制研究[D].广州：广州中医药大学，2011.
• [36]李健，张俭.川芎嗪对脓毒症大鼠心肌抑制干预作用的研究[J].中西医结合心脑血管病杂志，2016,14(3):263-265.
• [37]刘炳炜，胡炜，胡伟航，等.川芎嗪对脓毒症心肌损害患者心脏保护作用研究[J].浙江中西医结合杂志，2018,28(8):639-641.
• [38] Lafrance JP,Miller DR. Acute kidney injury associates with increased long-term mortality[J]. Journal of the American Society of Nephrology,2010,21(2):345-352.
• [39] Bagshaw SM,Uchino S,Bellomo R,et al. Septic acute kidney injury in critically ill patients:clinical characteristics and outcomes[J]. Clinical Journal of the American Society of Nephrology,2007,2(3):431-439.
• [40] Hoste EA,Kellum JA. Acute renal failure in the critically ill:impact on morbidity and mortality[M]//Sepsis,Kidney and Multiple Organ Dysfunction. Karger Publishers,2004,144:1-11.
• [41]刘海华，王锦权，刘宝，等.川芎嗪对脓毒症致兔急性肾损伤的保护作用[J].安徽医科大学学报，2010,45(2):213-216.
• [42]刘晓丽，霍展样，常全忠.川芎嗪对小鼠急性肾缺血再灌注损伤的影响[J].中国中西医结合肾病杂志，2002,3(9):507-509.
• [43] Seymour CW,Liu VX,Iwashyna TJ,et al. Assessment of clinical criteria for sepsis:for the third international consensus definitions for sepsis and septic shock(Sepsis-3)[J]. The Journal of the American Medical Association,2018,315(9):124.
• [44] Zhao GZ,Chen RB,Li B,et al. Clinical practice guideline on traditional Chinese medicine therapy alone or combined with antibiotics for sepsis[J]. Ann Transl Med,2019,7(6):122.